Trinity Biotech plc announced on September 9, 2026, that its Trinovium subsidiary signed a contract with Red Team Investments to supply advanced liquid cooling systems for AI data center infrastructure. The agreement establishes a framework for developing and deploying direct-to-chip liquid cooling solutions, including paid product supply as part of a U.S. commercial pilot focused on high-performance computing. This collaboration aims to provide real-world operating data to support product validation and broader commercialization in the rapidly growing data center liquid cooling market.

Trinity Biotech plc announced operational progress including the appointment of Jordi Romero as Head of Commercial Operations – Europe and the rollout of upgraded HbA1c column technology in three major markets. The company completed manufacturing approximately 9 million TrinScreen HIV tests under a new outsourced model and commenced production of Uni-Gold™ HIV, expecting margin improvements upon full scale-up. Additionally, the PrePsia™ patent portfolio expanded to nine granted patents in the U.S. and Europe. However, the filing disclosed that Trinity Biotech failed to regain compliance with Nasdaq’s $15 million market value of publicly held shares requirement by the August 18, 2026 deadline. Consequently, the company intends to request a hearing before a Hearings Panel to seek an extension until February 24, 2027, to avoid suspension or delisting from the Nasdaq Global Select Market. Trinity Biotech operates in the human diagnostics and diabetes management solutions industry.

Trinity Biotech secured a $7.0 million investment from Perceptive Credit Holdings III, L.P., comprising $2.5 million in new debt and $4.5 million of capitalized interest under an amendment to its credit agreement dated August 12, 2026. The company also regained compliance with Nasdaq’s minimum bid price requirement as of August 7, 2026, after maintaining a closing bid price of at least $1.00 per ADS for ten consecutive business days ending August 6, 2026. Preliminary revenues for the quarter ended June 30, 2026 were approximately $10.5 million. Trinity Biotech is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions.

Trinity Biotech plc announced a strategic collaboration agreement with Latch Medical Limited to develop precision therapeutic solutions for diabetes, obesity, and metabolic health. The partnership will combine Trinity Biotech's CGM+ wearable biosensor platform with Latch Medical's Pharma Latch™ intradermal drug delivery technology. Trinity Biotech has also agreed in principle to make a strategic equity investment in Latch Medical, supported by its largest financial investor, Perceptive Advisors. Trinity Biotech is a biotechnology company focused on human diagnostics and diabetes management solutions.

Trinity Biotech Plc announced a plan to change its ADS ratio from 1 ADS representing 20 Class A ordinary shares to 1 ADS representing 600 Class A ordinary shares, which has the effect of a 1-for-30 reverse ADS split. The change is intended to regain compliance with the Nasdaq minimum bid price requirement and facilitate investment from a broader pool of potential investors. The effective date is expected to be July 24, 2026. Trinity Biotech is a biotechnology company focused on human diagnostics and diabetes management solutions.